CPRX Catalyst Pharmaceuticals Inc

$20.91

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.

Website: https://catalystpharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1369568
Address
355 ALHAMBRA CIRCLE, SUITE 1250, CORAL GABLES, FL, US
Valuation
Market Cap
$2.75B
P/E Ratio
17.19
PEG Ratio
0.00
Price to Book
3.77
Performance
EPS
$1.31
Dividend Yield
—
Profit Margin
33.30%
ROE
29.40%
Technicals
50D MA
$22.63
200D MA
$20.96
52W High
$26.16
52W Low
$14.47
Fundamentals
Shares Outstanding
122M
Target Price
$33.88
Beta
0.79

CPRX EPS Estimates vs Actual

● Estimated
● Actual

CPRX News & Sentiment

Oct 01, 2025 • Zacks Commentary BULLISH
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Oct 01, 2025 • GlobeNewswire BULLISH
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and ...
Sep 25, 2025 • GlobeNewswire NEUTRAL
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
Ad hoc announcement pursuant to Art. 53 LR ...
Sep 23, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR ...
Sep 23, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR ...
Sep 23, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
Ad hoc announcement pursuant to Art. 53 LR ...
Sentiment Snapshot

Average Sentiment Score:

0.373
50 articles with scored sentiment

Overall Sentiment:

Bullish

CPRX Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Post market)
0.38 Surprise
  • Reported EPS: $0.70
  • Estimate: $0.32
  • Whisper: —
  • Surprise %: 118.8%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $0.35
  • Estimate: $0.30
  • Whisper: —
  • Surprise %: 16.7%
Aug 07, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $0.33
  • Estimate: $0.26
  • Whisper: —
  • Surprise %: 26.9%
May 08, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.19
  • Estimate: $0.17
  • Whisper: —
  • Surprise %: 11.8%
Feb 28, 2024
Dec 31, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $0.31
  • Estimate: $0.27
  • Whisper: —
  • Surprise %: 14.8%
Nov 08, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.29
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: -3.6%
Aug 09, 2023
Jun 30, 2023 (Post market)
0.11 Surprise
  • Reported EPS: $0.53
  • Estimate: $0.42
  • Whisper: —
  • Surprise %: 26.2%
May 10, 2023
Mar 31, 2023 (Post market)
-0.06 Surprise
  • Reported EPS: $0.26
  • Estimate: $0.32
  • Whisper: —
  • Surprise %: -18.8%
Mar 15, 2023
Dec 31, 2022 (Post market)
0.01 Surprise
  • Reported EPS: $0.22
  • Estimate: $0.21
  • Whisper: —
  • Surprise %: 4.8%

Financials